XERIS PHARMACEUTICALS RECEIVES U.S. FDA APPROVAL FOR GVOKE™ (GLUCAGON), THE FIRST READY-TO-USE STABLE LIQUID GLUCAGON FOR SEVERE HYPOGLYCEMIA
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations
Continua a leggere